| Literature DB >> 25827949 |
Manfred Kunz1, Inke R König2, Arne Schillert2, Jochen Kruppa2, Andreas Ziegler2, Harald Grallert3,4, Martina Müller-Nurasyid5,6,7, Wolfgang Lieb8, Andre Franke9, Annamari Ranki10, Jaana Panelius10, Sari Koskenmies10, Taina Hasan11, Juha Kere12,13, Ann-Charlotte Rönn14, Jan C Simon1, Enno Schmidt15, Joerg Wenzel16, Thomas Tüting16, Jennifer Landsberg16, Tanja Zeller17, Stefan Blankenberg17, Regine Gläser18, Nikolaos Patsinakidis19, Annegret Kuhn20, Saleh M Ibrahim15.
Abstract
Cutaneous lupus erythematosus (CLE) is a chronic autoimmune disease of the skin with typical clinical manifestations. Here, we genotyped 906 600 single nucleotide polymorphisms (SNPs) in 183 CLE cases and 1288 controls of Central European ancestry. Replication was performed for 13 SNPs in 219 case subjects and 262 controls from Finland. Association was particularly pronounced at 4 loci, all with genomewide significance (P < 5 × 10(-8) ): rs2187668 (PGWAS = 1.4 × 10(-12) ), rs9267531 (PGWAS = 4.7 × 10(-10) ), rs4410767 (PGWAS = 1.0 × 10(-9) ) and rs3094084 (PGWAS = 1.1 × 10(-9) ). All mentioned SNPs are located within the major histocompatibility complex (MHC) region of chromosome 6 and near genes of known immune functions or associations with other autoimmune diseases such as HLA-DQ alpha chain 1 (HLA-DQA1), MICA, MICB, MSH5, TRIM39 and RPP21. For example, TRIM39/RPP21 read through transcript is a known mediator of the interferon response, a central pathway involved in the pathogenesis of CLE and systemic lupus erythematosus (SLE). Taken together, this genomewide analysis of disease association of CLE identified candidate genes and genomic regions that may contribute to pathogenic mechanisms in CLE via dysregulated antigen presentation (HLA-DQA1), apoptosis regulation, RNA processing and interferon response (MICA, MICB, MSH5, TRIM39 and RPP21).Entities:
Keywords: autoimmune diseases; genetics; lupus; single nucleotide polymorphisms
Mesh:
Substances:
Year: 2015 PMID: 25827949 DOI: 10.1111/exd.12708
Source DB: PubMed Journal: Exp Dermatol ISSN: 0906-6705 Impact factor: 3.960